Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by tuesdaynightridon Apr 06, 2015 9:08am

253 Views

Post# 23599627

Rutherrin

Been away for a few weeks but there has been one topic of discussion over the last several days whose answer would appear critical to maximizing the results from human trials.

So, in short and as simply as I can state the question,
"Has anyone here been able to confirm with Theralase whether the ph1/2a trial will proceed WITh or WITHOUT TLD-1344 and pre-incubated Transferrin?

Having read most of what was posted on this board of this topic, I'm not sure of the answer.
If anyone here has received a response from Theralase on this topic, please inform.

Thank you!

Bullboard Posts

A junior copper-gold stock trading at a bargain of monumental proportions